Healthcare may be evolving at lightning speed, but affordability remains the toughest pill to swallow. From breakthrough drugs to digital care, innovation keeps rewriting medical possibilities. Yet ...

GoodRx (NASDAQ:GDRX – Free Report) had its price target cut by Truist Financial from $6.50 to $5.50 in a research note published on Thursday,Benzinga reports. They currently have a hold rating on the ...

Ratings for GoodRx Holdings (NASDAQ:GDRX) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

GoodRx Holdings Inc (NASDAQ:GDRX) stock is on the rise today, after an upgrade from RBC to "outperform" from "market perform," with a price-target hike to $10 from $8. This is just the latest in a ...

GoodRx stock rated a sell due to industry headwinds, cost growth outpacing revenue, and needing 12%+ growth to justify price. Q2 earnings expected to be in line with guidance, but long-term guidance ...

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

GoodRx GDRX recently rolled out a new e-commerce experience aimed at improving how consumers obtain their prescriptions through its platform. This upgraded system offers a more streamlined and ...

As the U.S. stock market wraps up a holiday-shortened week with notable gains across major indexes, investors are taking stock of opportunities that may have flown under the radar. Penny stocks, while ...

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible ...

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report)’s share price gapped down prior to trading on Friday . The stock had previously closed at $4.95, but opened at $4.81. GoodRx shares last traded at ...

JP Morgan analyst Lisa C. Gill revised her 2025 outlook on GoodRx Holdings (NASDAQ:GDRX) following the company’s first-quarter earnings. Gill reaffirmed an Overweight rating on the stock and ...